急性腎不全（ARF）の世界市場レポート 2025年

急性腎不全（ARF）市場規模は、今後数年間で力強い成長が見込まれます。2029年にはCAGR8.3％で90億9,000万米ドルに成長します。予測期間の成長は、在宅透析ソリューションの拡大、新興国市場、腎バイオマーカーの開発、新治療薬の研究開発増加、非侵襲的診断の需要増などに起因すると考えられます。主な動向としては、持続的腎代替療法（CRRT）の革新、腎組織の3Dバイオプリンティングの進歩、ウェアラブルバイオセンサーの開発、次世代透析装置、ナノテクノロジーによるドラッグデリバリーシステムなどが挙げられます。

慢性腎臓病の有病率の上昇は、急性腎不全（ARF）市場の成長を促進すると予想されます。慢性腎臓病（CKD）は、腎臓が損傷を受け、血液を効果的にろ過する能力を失う長期的な状態です。CKDの発生が増加しているのは、糖尿病、高血圧、肥満、高齢化、および生活習慣に関連する要因が世界的に増加していることが主な原因です。急性腎不全は、腎機能の突然の喪失を特徴とし、適切に管理されなければ、腎組織に恒久的な損傷を与え、ろ過効率を低下させ、腎機能障害を進行させるリスクを高めることにより、CKDの重大な一因となったり、悪化させたりする可能性があります。例えば、2023年6月、英国を拠点とする非営利団体Kidney Research UKは、英国では人口の10％を超える約720万人が現在慢性腎臓病を患っていると報告しました。そのうち325万人が進行期で、さらに390万人が初期段階にあります。2033年までには、CKD患者数は761万人に増加すると予測されています。その結果、慢性腎臓病の有病率の増加が急性腎不全（ARF）市場の拡大に拍車をかけています。

急性腎不全（ARF）市場の主要企業は、重症急性腎障害（AKI）治療におけるリーチを広げ、その地位を確固たるものにするため、新薬の規制当局による承認を優先しています。薬事承認とは、政府機関または規制当局から、治療法、医薬品、または医療機器の販売と一般使用を正式に認可されることです。例えば、2024年2月、米国を拠点とする臨床段階のバイオ医薬品会社であるカルチメディカ社は、オーソラの第2相臨床試験のための治験薬（IND）申請についてFDAの承認を受けた。この試験は、死亡率の高い急性低酸素性呼吸不全（AHRF）に伴う重症急性腎障害（AKI）に対するオーソラの有効性を評価することを目的としています。KOURAGE試験として知られるこの無作為化二重盲検プラセボ対照試験は、AHRFを併発したステージ2および3のAKI患者約150人を登録します。本試験では、1日5回の投与によるオーソラの有効性を、治療後30日まで患者が人工呼吸器や透析を必要とせずに生存している日数を測定することで評価します。

目次

第1章 エグゼクティブサマリー

第2章 市場の特徴

第3章 市場動向と戦略

第4章 市場- マクロ経済シナリオ金利、インフレ、地政学、新型コロナウイルス感染症の影響と回復が市場に与える影響を含むマクロ経済シナリオ

第5章 世界の成長分析と戦略分析フレームワーク

• 世界急性腎不全（ARF） PESTEL分析（政治、社会、技術、環境、法的要因、促進要因と抑制要因）
• 最終用途産業の分析
• 世界の急性腎不全（ARF）市場：成長率分析
• 世界の急性腎不全（ARF）市場の実績：規模と成長, 2019-2024
• 世界の急性腎不全（ARF）市場の予測：規模と成長, 2024-2029, 2034F
• 世界急性腎不全（ARF）総アドレス可能市場（TAM）

第6章 市場セグメンテーション

• 世界の急性腎不全（ARF）市場：疾患タイプ別、実績と予測, 2019-2024, 2024-2029F, 2034F
• 腎前性急性腎不全
• 急性腎不全
• 腎後性急性腎不全
• 世界の急性腎不全（ARF）市場薬剤の種類別、実績と予測, 2019-2024, 2024-2029F, 2034F
• 利尿剤
• 血管収縮薬
• 赤血球造血刺激因子（ESAS）
• リン酸結合剤
• カルシウムとビタミンDのサプリメント
• 抗生物質
• その他医薬品
• 世界の急性腎不全（ARF）市場：投与経路別、実績と予測, 2019-2024, 2024-2029F, 2034F
• オーラル
• 静脈内
• 世界の急性腎不全（ARF）市場診断別、実績と予測, 2019-2024, 2024-2029F, 2034F
• コンピュータ断層撮影（CT）スキャン
• 腎生検
• 超音波
• 世界の急性腎不全（ARF）市場：エンドユーザー別、実績と予測, 2019-2024, 2024-2029F, 2034F
• クリニック
• 病院
• 在宅ヘルスケア
• その他のエンドユーザー
• 世界の急性腎不全（ARF）市場腎前性急性腎不全の種類別サブセグメンテーション、実績と予測, 2019-2024, 2024-2029F, 2034F
• 血液量減少
• 心拍出量の減少
• 腎動脈狭窄
• 世界の急性腎不全（ARF）市場急性腎不全のサブセグメンテーション（タイプ別）、実績と予測, 2019-2024, 2024-2029F, 2034F
• 急性尿細管壊死
• 糸球体腎炎
• 間質性腎炎
• 世界の急性腎不全（ARF）市場腎後性急性腎不全の病型別サブセグメンテーション、実績と予測, 2019-2024, 2024-2029F, 2034F
• 閉塞性尿路疾患
• 膀胱出口閉塞
• 腎臓結石

第7章 地域別・国別分析

• 世界の急性腎不全（ARF）市場：地域別、実績と予測, 2019-2024, 2024-2029F, 2034F
• 世界の急性腎不全（ARF）市場：国別、実績と予測, 2019-2024, 2024-2029F, 2034F

第8章 アジア太平洋市場

第9章 中国市場

第10章 インド市場

第11章 日本市場

第12章 オーストラリア市場

第13章 インドネシア市場

第14章 韓国市場

第15章 西欧市場

第16章 英国市場

第17章 ドイツ市場

第18章 フランス市場

第19章 イタリア市場

第20章 スペイン市場

第21章 東欧市場

第22章 ロシア市場

第23章 北米市場

第24章 米国市場

第25章 カナダ市場

第26章 南米市場

第27章 ブラジル市場

第28章 中東市場

第29章 アフリカ市場

第30章 競合情勢と企業プロファイル

• 急性腎不全（ARF）市場：競合情勢
• 急性腎不全（ARF）市場：企業プロファイル
  • Pfizer Inc. Overview, Products and Services, Strategy and Financial Analysis
  • Novartis AG Overview, Products and Services, Strategy and Financial Analysis
  • LG Chem Ltd. Overview, Products and Services, Strategy and Financial Analysis
  • Medtronic plc Overview, Products and Services, Strategy and Financial Analysis
  • Fresenius Medical Care AG & Co. KGaA Overview, Products and Services, Strategy and Financial Analysis

第31章 その他の大手企業と革新的企業

• Asahi Kasei Corporation
• Baxter International Inc.
• Astellas Pharma Inc.
• Syensqo
• Dr. Reddy's Laboratories Limited
• Zydus Lifesciences Limited
• NIKKISO Co., Ltd.
• Quark Pharmaceuticals Inc.
• NIPRO Corporation
• Alloksys Life Sciences B.V.
• AM-Pharma B.V.
• Sentien Biotechnologies
• MediBeacon LLC
• Angion Biomedica Corp.
• Atox Bio Ltd.

第32章 世界の市場競合ベンチマーキングとダッシュボード

第33章 主要な合併と買収

第34章 最近の市場動向

第35章 市場の潜在力が高い国、セグメント、戦略

• 急性腎不全（ARF）市場2029：新たな機会を提供する国
• 急性腎不全（ARF）市場2029：新たな機会を提供するセグメント
• 急性腎不全（ARF）市場2029：成長戦略
  • 市場動向に基づく戦略
  • 競合の戦略

第36章 付録

Acute renal failure (ARF), also referred to as acute kidney injury (AKI), is a sudden and rapid decline in kidney function that occurs over a few hours or days. Treatment for ARF involves various approaches, including medication, fluid management, and dialysis, to aid in restoring kidney function and preventing further complications.

The primary types of acute renal failure (ARF) include prerenal, renal, and postrenal ARF. Prerenal ARF results from conditions that impact blood flow to the kidneys, such as dehydration or heart failure. The treatment options consist of various drug classes, including diuretics, vasopressors, erythropoiesis-stimulating agents (ESAs), phosphate binders, calcium and vitamin D supplements, antibiotics, and other medications. These drugs are administered through different routes, such as oral and intravenous. Diagnosis methods include computed tomography (CT) scans, kidney biopsies, and ultrasounds. ARF treatment is utilized by various end users, including clinics, hospitals, home healthcare providers, and others.

The acute renal failure (ARF) market research report is one of a series of new reports from The Business Research Company that provides acute renal failure (ARF) market statistics, including acute renal failure (ARF) industry global market size, regional shares, competitors with acute renal failure (ARF) market share, detailed acute renal failure (ARF) market segments, market trends and opportunities, and any further data you may need to thrive in the acute renal failure (ARF) industry. This acute renal failure (ARF) market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

The acute renal failure (ARF) market size has grown strongly in recent years. It will grow from $6.09 billion in 2024 to $6.62 billion in 2025 at a compound annual growth rate (CAGR) of 8.6%. The growth in the historic period can be attributed to the rising aging population, increasing incidence of sepsis, advancements in diagnostic capabilities, government healthcare initiatives, and the growing number of nephrotoxic medication-related cases.

The acute renal failure (ARF) market size is expected to see strong growth in the next few years. It will grow to $9.09 billion in 2029 at a compound annual growth rate (CAGR) of 8.3%. The growth in the forecast period can be attributed to the expansion of home-based dialysis solutions, emerging markets, the development of renal biomarkers, increased R&D for new therapeutic drugs, and rising demand for non-invasive diagnostics. Major trends include innovations in continuous renal replacement therapy (CRRT), advancements in 3D bioprinting of renal tissue, the development of wearable biosensors, next-generation dialysis machines, and nanotechnology-driven drug delivery systems.

The rising prevalence of chronic kidney diseases is expected to drive growth in the acute renal failure (ARF) market. Chronic kidney disease (CKD) is a long-term condition in which the kidneys become damaged and lose their ability to filter blood effectively. The increasing occurrence of CKD is largely attributed to the rising rates of diabetes, hypertension, obesity, aging populations, and lifestyle-related factors worldwide. Acute renal failure, which is characterized by the sudden loss of kidney function, can significantly contribute to or worsen CKD by causing permanent damage to kidney tissues, reducing filtration efficiency, and heightening the risk of progressive kidney dysfunction if not properly managed. For example, in June 2023, Kidney Research UK, a UK-based non-profit organization, reported that approximately 7.2 million people in the UK over 10% of the population are currently living with chronic kidney disease. Among them, 3.25 million are in the advanced stages of the disease, while another 3.9 million are in the early stages. By 2033, the number of individuals affected by CKD is projected to increase to 7.61 million. As a result, the growing prevalence of chronic kidney diseases is fueling the expansion of the acute renal failure (ARF) market.

Leading companies in the acute renal failure (ARF) market are prioritizing regulatory approvals for new drugs to extend their reach and solidify their position in treating severe acute kidney injury (AKI). Regulatory approvals involve formal authorization from governmental or regulatory agencies for the marketing and public use of medical treatments, drugs, or devices. For example, in February 2024, CalciMedica, a US-based clinical-stage biopharmaceutical company, received FDA approval for an Investigational New Drug (IND) application for a Phase 2 trial of Auxora. This trial aims to assess Auxora's efficacy in treating severe acute kidney injury (AKI) associated with acute hypoxemic respiratory failure (AHRF), a condition with a high mortality rate. Known as the KOURAGE trial, this randomized, double-blind, placebo-controlled study will enroll approximately 150 patients with Stage 2 and 3 AKI who also have AHRF. The study will evaluate the effectiveness of Auxora over five daily doses by measuring the number of days patients remain alive without the need for ventilators or dialysis up to 30 days post-treatment.

In June 2023, Elicio Therapeutics Inc., a US-based biotechnology company, completed a merger with Angion Biomedica Corp. to strengthen its immunotherapy pipeline. Through this merger, Elicio Therapeutics seeks to expand its portfolio by leveraging Angion Biomedica's expertise and resources, accelerating the development of innovative treatments for various diseases, and advancing novel therapies within the biotechnology sector. Angion Biomedica is a US-based biopharmaceutical company specializing in the development of treatments for acute renal failure (ARF).

Major players in the acute renal failure (arf) market are Pfizer Inc., Novartis AG, LG Chem Ltd., Medtronic plc, Fresenius Medical Care AG & Co. KGaA, Asahi Kasei Corporation, Baxter International Inc., Astellas Pharma Inc., Syensqo, Dr. Reddy's Laboratories Limited, Zydus Lifesciences Limited, NIKKISO Co., Ltd., Quark Pharmaceuticals Inc., NIPRO Corporation, Alloksys Life Sciences B.V., AM-Pharma B.V., Sentien Biotechnologies, MediBeacon LLC, Angion Biomedica Corp., and Atox Bio Ltd.

North America was the largest region in the acute renal failure (ARF) market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in acute renal failure (ARF) report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East and Africa.

The countries covered in the acute renal failure (ARF) market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

The acute renal failure (ARF) market consists of revenues earned by entities by providing services such as dialysis treatment, emergency care, renal replacement therapies, post-acute care for kidney recovery, and hospital-based interventions. The market value includes the value of related goods sold by the service provider or included within the service offering. The acute renal failure (ARF) market also includes sales of dialysis equipment, normal saline, urine test kits, and urinary catheters. Values in this market are 'factory gate' values, that is, the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

Acute Renal Failure (ARF) Global Market Report 2025 from The Business Research Company provides strategists, marketers and senior management with the critical information they need to assess the market.

This report focuses on acute renal failure (arf) market which is experiencing strong growth. The report gives a guide to the trends which will be shaping the market over the next ten years and beyond.

Reasons to Purchase

• Gain a truly global perspective with the most comprehensive report available on this market covering 15 geographies.
• Assess the impact of key macro factors such as conflict, pandemic and recovery, inflation and interest rate environment and the 2nd Trump presidency.
• Create regional and country strategies on the basis of local data and analysis.
• Identify growth segments for investment.
• Outperform competitors using forecast data and the drivers and trends shaping the market.
• Understand customers based on the latest market shares.
• Benchmark performance against key competitors.
• Suitable for supporting your internal and external presentations with reliable high quality data and analysis
• Report will be updated with the latest data and delivered to you within 2-3 working days of order along with an Excel data sheet for easy data extraction and analysis.
• All data from the report will also be delivered in an excel dashboard format.

Where is the largest and fastest growing market for acute renal failure (arf) ? How does the market relate to the overall economy, demography and other similar markets? What forces will shape the market going forward? The acute renal failure (arf) market global report from the Business Research Company answers all these questions and many more.

The report covers market characteristics, size and growth, segmentation, regional and country breakdowns, competitive landscape, market shares, trends and strategies for this market. It traces the market's historic and forecast market growth by geography.

• The market characteristics section of the report defines and explains the market.
• The market size section gives the market size ($b) covering both the historic growth of the market, and forecasting its development.
• The forecasts are made after considering the major factors currently impacting the market. These include:

The forecasts are made after considering the major factors currently impacting the market. These include the Russia-Ukraine war, rising inflation, higher interest rates, and the legacy of the COVID-19 pandemic.

• Market segmentations break down the market into sub markets.
• The regional and country breakdowns section gives an analysis of the market in each geography and the size of the market by geography and compares their historic and forecast growth. It covers the growth trajectory of COVID-19 for all regions, key developed countries and major emerging markets.
• The competitive landscape chapter gives a description of the competitive nature of the market, market shares, and a description of the leading companies. Key financial deals which have shaped the market in recent years are identified.
• The trends and strategies section analyses the shape of the market as it emerges from the crisis and suggests how companies can grow as the market recovers.

Scope

• Markets Covered:1) By Disease Type: Prerenal Acute Renal Failure; Renal Acute Renal Failure; Postrenal Acute Renal Failure
• 2) By Drug Type: Diuretics; Vasopressors; Erythropoiesis-Stimulating Agents (ESAS); Phosphate Binders; Calcium and Vitamin D Supplements; Antibiotics; Others Drugs
• 3) By Route of Administration: Oral; Intravenous
• 4) By Diagnosis: Computed Tomography (CT) Scan; Kidney Biopsy; Ultrasound
• 5) By End-Users: Clinics; Hospitals; Home Healthcare; Others End-Users
• Subsegments:
• 1) By Prerenal Acute Renal Failure: Hypovolemia; Decreased Cardiac Output; Renal Artery Stenosis
• 2) By Renal Acute Renal Failure: Acute Tubular Necrosis; Glomerulonephritis; Interstitial Nephritis
• 3) By Postrenal Acute Renal Failure: Obstructive Uropathy; Bladder Outlet Obstruction; Kidney Stones
• Companies Mentioned: Pfizer Inc.; Novartis AG; LG Chem Ltd.; Medtronic plc; Fresenius Medical Care AG & Co. KGaA
• Countries: Australia; Brazil; China; France; Germany; India; Indonesia; Japan; Russia; South Korea; UK; USA; Canada; Italy; Spain
• Regions: Asia-Pacific; Western Europe; Eastern Europe; North America; South America; Middle East; Africa
• Time series: Five years historic and ten years forecast.
• Data: Ratios of market size and growth to related markets, GDP proportions, expenditure per capita,
• Data segmentations: country and regional historic and forecast data, market share of competitors, market segments.
• Sourcing and Referencing: Data and analysis throughout the report is sourced using end notes.
• Delivery format: PDF, Word and Excel Data Dashboard.

Table of Contents

1. Executive Summary

2. Acute Renal Failure (ARF) Market Characteristics

3. Acute Renal Failure (ARF) Market Trends And Strategies

4. Acute Renal Failure (ARF) Market - Macro Economic Scenario Macro Economic Scenario Including The Impact Of Interest Rates, Inflation, Geopolitics And Covid And Recovery On The Market

5. Global Acute Renal Failure (ARF) Growth Analysis And Strategic Analysis Framework

• 5.1. Global Acute Renal Failure (ARF) PESTEL Analysis (Political, Social, Technological, Environmental and Legal Factors, Drivers and Restraints)
• 5.2. Analysis Of End Use Industries
• 5.3. Global Acute Renal Failure (ARF) Market Growth Rate Analysis
• 5.4. Global Acute Renal Failure (ARF) Historic Market Size and Growth, 2019 - 2024, Value ($ Billion)
• 5.5. Global Acute Renal Failure (ARF) Forecast Market Size and Growth, 2024 - 2029, 2034F, Value ($ Billion)
• 5.6. Global Acute Renal Failure (ARF) Total Addressable Market (TAM)

6. Acute Renal Failure (ARF) Market Segmentation

• 6.1. Global Acute Renal Failure (ARF) Market, Segmentation By Disease Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Prerenal Acute Renal Failure
• Renal Acute Renal Failure
• Postrenal Acute Renal Failure
• 6.2. Global Acute Renal Failure (ARF) Market, Segmentation By Drug Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Diuretics
• Vasopressors
• Erythropoiesis-Stimulating Agents (ESAS)
• Phosphate Binders
• Calcium and Vitamin D Supplements
• Antibiotics
• Others Drugs
• 6.3. Global Acute Renal Failure (ARF) Market, Segmentation By Route of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Oral
• Intravenous
• 6.4. Global Acute Renal Failure (ARF) Market, Segmentation By Diagnosis, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Computed Tomography (CT) Scan
• Kidney Biopsy
• Ultrasound
• 6.5. Global Acute Renal Failure (ARF) Market, Segmentation By End-Users, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Clinics
• Hospitals
• Home Healthcare
• Others End-Users
• 6.6. Global Acute Renal Failure (ARF) Market, Sub-Segmentation Of Prerenal Acute Renal Failure, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Hypovolemia
• Decreased Cardiac Output
• Renal Artery Stenosis
• 6.7. Global Acute Renal Failure (ARF) Market, Sub-Segmentation Of Renal Acute Renal Failure, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Acute Tubular Necrosis
• Glomerulonephritis
• Interstitial Nephritis
• 6.8. Global Acute Renal Failure (ARF) Market, Sub-Segmentation Of Postrenal Acute Renal Failure, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Obstructive Uropathy
• Bladder Outlet Obstruction
• Kidney Stones

7. Acute Renal Failure (ARF) Market Regional And Country Analysis

• 7.1. Global Acute Renal Failure (ARF) Market, Split By Region, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 7.2. Global Acute Renal Failure (ARF) Market, Split By Country, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

8. Asia-Pacific Acute Renal Failure (ARF) Market

• 8.1. Asia-Pacific Acute Renal Failure (ARF) Market Overview
• Region Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
• 8.2. Asia-Pacific Acute Renal Failure (ARF) Market, Segmentation By Disease Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 8.3. Asia-Pacific Acute Renal Failure (ARF) Market, Segmentation By Drug Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 8.4. Asia-Pacific Acute Renal Failure (ARF) Market, Segmentation By Route of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

9. China Acute Renal Failure (ARF) Market

• 9.1. China Acute Renal Failure (ARF) Market Overview
• 9.2. China Acute Renal Failure (ARF) Market, Segmentation By Disease Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion
• 9.3. China Acute Renal Failure (ARF) Market, Segmentation By Drug Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion
• 9.4. China Acute Renal Failure (ARF) Market, Segmentation By Route of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion

10. India Acute Renal Failure (ARF) Market

• 10.1. India Acute Renal Failure (ARF) Market, Segmentation By Disease Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 10.2. India Acute Renal Failure (ARF) Market, Segmentation By Drug Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 10.3. India Acute Renal Failure (ARF) Market, Segmentation By Route of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

11. Japan Acute Renal Failure (ARF) Market

• 11.1. Japan Acute Renal Failure (ARF) Market Overview
• 11.2. Japan Acute Renal Failure (ARF) Market, Segmentation By Disease Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 11.3. Japan Acute Renal Failure (ARF) Market, Segmentation By Drug Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 11.4. Japan Acute Renal Failure (ARF) Market, Segmentation By Route of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

12. Australia Acute Renal Failure (ARF) Market

• 12.1. Australia Acute Renal Failure (ARF) Market, Segmentation By Disease Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 12.2. Australia Acute Renal Failure (ARF) Market, Segmentation By Drug Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 12.3. Australia Acute Renal Failure (ARF) Market, Segmentation By Route of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

13. Indonesia Acute Renal Failure (ARF) Market

• 13.1. Indonesia Acute Renal Failure (ARF) Market, Segmentation By Disease Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 13.2. Indonesia Acute Renal Failure (ARF) Market, Segmentation By Drug Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 13.3. Indonesia Acute Renal Failure (ARF) Market, Segmentation By Route of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

14. South Korea Acute Renal Failure (ARF) Market

• 14.1. South Korea Acute Renal Failure (ARF) Market Overview
• 14.2. South Korea Acute Renal Failure (ARF) Market, Segmentation By Disease Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 14.3. South Korea Acute Renal Failure (ARF) Market, Segmentation By Drug Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 14.4. South Korea Acute Renal Failure (ARF) Market, Segmentation By Route of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

15. Western Europe Acute Renal Failure (ARF) Market

• 15.1. Western Europe Acute Renal Failure (ARF) Market Overview
• 15.2. Western Europe Acute Renal Failure (ARF) Market, Segmentation By Disease Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 15.3. Western Europe Acute Renal Failure (ARF) Market, Segmentation By Drug Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 15.4. Western Europe Acute Renal Failure (ARF) Market, Segmentation By Route of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

16. UK Acute Renal Failure (ARF) Market

• 16.1. UK Acute Renal Failure (ARF) Market, Segmentation By Disease Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 16.2. UK Acute Renal Failure (ARF) Market, Segmentation By Drug Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 16.3. UK Acute Renal Failure (ARF) Market, Segmentation By Route of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

17. Germany Acute Renal Failure (ARF) Market

• 17.1. Germany Acute Renal Failure (ARF) Market, Segmentation By Disease Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 17.2. Germany Acute Renal Failure (ARF) Market, Segmentation By Drug Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 17.3. Germany Acute Renal Failure (ARF) Market, Segmentation By Route of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

18. France Acute Renal Failure (ARF) Market

• 18.1. France Acute Renal Failure (ARF) Market, Segmentation By Disease Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 18.2. France Acute Renal Failure (ARF) Market, Segmentation By Drug Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 18.3. France Acute Renal Failure (ARF) Market, Segmentation By Route of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

19. Italy Acute Renal Failure (ARF) Market

• 19.1. Italy Acute Renal Failure (ARF) Market, Segmentation By Disease Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 19.2. Italy Acute Renal Failure (ARF) Market, Segmentation By Drug Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 19.3. Italy Acute Renal Failure (ARF) Market, Segmentation By Route of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

20. Spain Acute Renal Failure (ARF) Market

• 20.1. Spain Acute Renal Failure (ARF) Market, Segmentation By Disease Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 20.2. Spain Acute Renal Failure (ARF) Market, Segmentation By Drug Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 20.3. Spain Acute Renal Failure (ARF) Market, Segmentation By Route of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

21. Eastern Europe Acute Renal Failure (ARF) Market

• 21.1. Eastern Europe Acute Renal Failure (ARF) Market Overview
• 21.2. Eastern Europe Acute Renal Failure (ARF) Market, Segmentation By Disease Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 21.3. Eastern Europe Acute Renal Failure (ARF) Market, Segmentation By Drug Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 21.4. Eastern Europe Acute Renal Failure (ARF) Market, Segmentation By Route of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

22. Russia Acute Renal Failure (ARF) Market

• 22.1. Russia Acute Renal Failure (ARF) Market, Segmentation By Disease Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 22.2. Russia Acute Renal Failure (ARF) Market, Segmentation By Drug Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 22.3. Russia Acute Renal Failure (ARF) Market, Segmentation By Route of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

23. North America Acute Renal Failure (ARF) Market

• 23.1. North America Acute Renal Failure (ARF) Market Overview
• 23.2. North America Acute Renal Failure (ARF) Market, Segmentation By Disease Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 23.3. North America Acute Renal Failure (ARF) Market, Segmentation By Drug Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 23.4. North America Acute Renal Failure (ARF) Market, Segmentation By Route of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

24. USA Acute Renal Failure (ARF) Market

• 24.1. USA Acute Renal Failure (ARF) Market Overview
• 24.2. USA Acute Renal Failure (ARF) Market, Segmentation By Disease Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 24.3. USA Acute Renal Failure (ARF) Market, Segmentation By Drug Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 24.4. USA Acute Renal Failure (ARF) Market, Segmentation By Route of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

25. Canada Acute Renal Failure (ARF) Market

• 25.1. Canada Acute Renal Failure (ARF) Market Overview
• 25.2. Canada Acute Renal Failure (ARF) Market, Segmentation By Disease Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 25.3. Canada Acute Renal Failure (ARF) Market, Segmentation By Drug Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 25.4. Canada Acute Renal Failure (ARF) Market, Segmentation By Route of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

26. South America Acute Renal Failure (ARF) Market

• 26.1. South America Acute Renal Failure (ARF) Market Overview
• 26.2. South America Acute Renal Failure (ARF) Market, Segmentation By Disease Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 26.3. South America Acute Renal Failure (ARF) Market, Segmentation By Drug Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 26.4. South America Acute Renal Failure (ARF) Market, Segmentation By Route of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

27. Brazil Acute Renal Failure (ARF) Market

• 27.1. Brazil Acute Renal Failure (ARF) Market, Segmentation By Disease Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 27.2. Brazil Acute Renal Failure (ARF) Market, Segmentation By Drug Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 27.3. Brazil Acute Renal Failure (ARF) Market, Segmentation By Route of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

28. Middle East Acute Renal Failure (ARF) Market

• 28.1. Middle East Acute Renal Failure (ARF) Market Overview
• 28.2. Middle East Acute Renal Failure (ARF) Market, Segmentation By Disease Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 28.3. Middle East Acute Renal Failure (ARF) Market, Segmentation By Drug Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 28.4. Middle East Acute Renal Failure (ARF) Market, Segmentation By Route of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

29. Africa Acute Renal Failure (ARF) Market

• 29.1. Africa Acute Renal Failure (ARF) Market Overview
• 29.2. Africa Acute Renal Failure (ARF) Market, Segmentation By Disease Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 29.3. Africa Acute Renal Failure (ARF) Market, Segmentation By Drug Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 29.4. Africa Acute Renal Failure (ARF) Market, Segmentation By Route of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

30. Acute Renal Failure (ARF) Market Competitive Landscape And Company Profiles

• 30.1. Acute Renal Failure (ARF) Market Competitive Landscape
• 30.2. Acute Renal Failure (ARF) Market Company Profiles
  • 30.2.1. Pfizer Inc. Overview, Products and Services, Strategy and Financial Analysis
  • 30.2.2. Novartis AG Overview, Products and Services, Strategy and Financial Analysis
  • 30.2.3. LG Chem Ltd. Overview, Products and Services, Strategy and Financial Analysis
  • 30.2.4. Medtronic plc Overview, Products and Services, Strategy and Financial Analysis
  • 30.2.5. Fresenius Medical Care AG & Co. KGaA Overview, Products and Services, Strategy and Financial Analysis

31. Acute Renal Failure (ARF) Market Other Major And Innovative Companies

• 31.1. Asahi Kasei Corporation
• 31.2. Baxter International Inc.
• 31.3. Astellas Pharma Inc.
• 31.4. Syensqo
• 31.5. Dr. Reddy's Laboratories Limited
• 31.6. Zydus Lifesciences Limited
• 31.7. NIKKISO Co., Ltd.
• 31.8. Quark Pharmaceuticals Inc.
• 31.9. NIPRO Corporation
• 31.10. Alloksys Life Sciences B.V.
• 31.11. AM-Pharma B.V.
• 31.12. Sentien Biotechnologies
• 31.13. MediBeacon LLC
• 31.14. Angion Biomedica Corp.
• 31.15. Atox Bio Ltd.

32. Global Acute Renal Failure (ARF) Market Competitive Benchmarking And Dashboard

33. Key Mergers And Acquisitions In The Acute Renal Failure (ARF) Market

34. Recent Developments In The Acute Renal Failure (ARF) Market

35. Acute Renal Failure (ARF) Market High Potential Countries, Segments and Strategies

• 35.1 Acute Renal Failure (ARF) Market In 2029 - Countries Offering Most New Opportunities
• 35.2 Acute Renal Failure (ARF) Market In 2029 - Segments Offering Most New Opportunities
• 35.3 Acute Renal Failure (ARF) Market In 2029 - Growth Strategies
  • 35.3.1 Market Trend Based Strategies
  • 35.3.2 Competitor Strategies

36. Appendix

• 36.1. Abbreviations
• 36.2. Currencies
• 36.3. Historic And Forecast Inflation Rates
• 36.4. Research Inquiries
• 36.5. The Business Research Company
• 36.6. Copyright And Disclaimer